'This year, we've had encouraging news about integrated, comprehensive approaches for treating people with first episode psychosis, most recently from a major NIMH initiative, the Recovery After an Initial Schizophrenia Episode, or RAISE project. RAISE looked at coordinated specialty care for first episode psychosis.'
'The study is undoubtedly of value in furthering our understanding of the brain structure of people who experience abnormal perceptions. However, further research is needed to investigate whether this is a risk factor or a consequence of the condition. As such, at present it has no preventative or therapeutic implications.'
The authors compared the effectiveness of initiating treatment with either clozapine or a standard antipsychotic among adults with evidence of treatment-resistant schizophrenia in routine clinical practice. Login using your SSSFT NHS OpenAthens for full text. SSOTP - request a copy of the article from the library - www.sssft.nhs.uk/library
The question of whether there are significant changes in brain anatomy and function at illness onset and over the early course of schizophrenia is a crucial issue with broad implications for prognosis, patient care, and models of illness pathophysiology. Login using your SSSFT NHS OpenAthens for full text. SSOTP - request a copy of the article from the library - www.sssft.nhs.uk/library
Although mortality related to psychotropic medications has received much attention in recent years, little is known about the relationship between risk of death and cumulative antipsychotic load, and even less about the relationship between mortality and cumulative exposure to antidepressants or benzodiazepines. The authors examined these relationships using nationwide databases. Login using your SSSFT NHS OpenAthens for full text. SSOTP - request a copy of the article from the library - www.sssft.nhs.uk/library
Auditory verbal hallucinations (AVHs) are core features of psychotic illness and remain significant in predicting poor outcome and risk. There has been a wide range of approaches to understanding these experiences.To read the full article, log in using your NHS OpenAthens details
We're currently making some changes in the background of our email updates to solve some problems we've been having recently. During our testing phase this may automatically generate some alerts, which will show below, but you can ignore these! If all goes according to plan we will be resuming normal service in the next week…
Armodafinil (Nuvigil®) is an eugeroic drug made by Cephalon, FDA-approved 6/15/2007. Clinical trials for its use in bipolar disorder, cognition in schizophrenia, excessive fatigue in Parkinson's & cancer, begin. Patent expires 2023.
A. Laenen, T. Vangeneugden, H. Geys, and G. Molenberghs. The British journal of mathematical and statistical psychology, 59 (Pt 1):
113-31(May 2006)Mesures de concordància; Online; ICC; Psiquiatria.